膀胱癌多药耐药基因与p53基因表达的临床意义  

Clinical significance of MDR1 and p53 gene expression in bladder transitional cell carcinoma

作　　者：阳东荣 殷福兴[1] 颜纯海[1] 李玲玲[1] 单玉喜[1] 

机构地区：[1]苏州医学院附属第二医院泌尿外科,215004

出　　处：《江苏医药》2000年第6期423-424,共2页Jiangsu Medical Journal

摘　　要：目的　探讨膀胱癌中多药耐药基因 (MDR1)与 p5 3基因表达的临床意义。 方法　采用免疫组化 (SABC)法对 35例膀胱移行细胞癌中MDR1表达产物P GP与p5 3基因产物 p5 3蛋白进行了检测。结果　 35例膀胱移行细胞癌中P GP、p5 3阳性率分别为 40 %和 48 6 % ,随膀胱癌的病理分级和临床分期而增高。T2 ～T4 期同Tis～T1期相比 ,MDR1及p5 3的表达均有显著性差异。MDR1与p5 3的表达无相关性。同时表达MDR1及 p5 3的患者预后较差。 结论　膀胱癌中MDR1与p5 3的表达无相关性。临床检测MDR1及p5 3可对膀胱癌患者提供更多的预后信息。Objective To study the clinical significance of the expression of multidrug resistance gene(MDR1)and p53 gene in bladder transitional cell carcinoma(BTCC). Methods P GP and p53 proteins were detected by immunohistochemical(SABC)methods in 35 BTCC specimens.Results The positive staining of P GP and p53 were 40% and 48 6% of all the specimens.The expression of MDR1 and p53 had a statistical significant difference between stages T 2～T 4 and Tis～T 1 BTCC.No correlation between MDR1 and p53 gene expression in BTCC was found.The coexpression of MDR1 and p53 had a poor prognosis.Conclusion It is shown that the coexpression of MDR1 and p53 may contribute to the prognostic value of BTCC.

关 键 词：膀胱肿瘤 P53基因 多药耐药基因 

分 类 号：R737.14[医药卫生—肿瘤]